Developing live bacterial medicines for respiratory and women’s health
Respiratory and vaginal infections can recur and disrupt daily life, while repeated antibiotic use can disturb protective bacteria. Growing antimicrobial resistance makes some infections harder to treat, leaving patients with fewer effective options and a need for repeated courses of medication.
aMylla is developing medicines made from beneficial live bacteria for respiratory and women’s health. Its selected strains are designed to strengthen protective tissue barriers, support immune responses and limit harmful microbes at the site of infection.
What stands out about aMylla
Completed initial human testing of live-bacterial therapies before advancing its first product toward further clinical studies.
Formed in 2025 from University of Antwerp and KU Leuven research to develop live-bacterial medicines for respiratory and women’s health.
Co-founder Sarah Lebeer previously co-founded YUN, translating University of Antwerp microbiome research into probiotic skincare products.
Co-founder Ilke De Boeck completed doctoral research on airway bacteria and probiotics for chronic rhinosinusitis at the University of Antwerp.
Co-founder Sarah Lebeer won an ERC Starting Grant for Lacto-Be in 2020, researching lactobacilli and launching the Isala vaginal microbiome project.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.